Kevin Haigis, PhD

Kevin Haigis, PhD, is the Chief Scientific Officer at Dana-Farber Cancer Institute and Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School. Dr. Haigis received his PhD from the University of Wisconsin – Madison where, as a student in the laboratory of Dr. William Dove, he studied the chromosomal mechanisms governing tumor initiation in the ApcMin model of intestinal tumorigenesis. He performed his post-doctoral work in the laboratory of Dr. Tyler Jacks at the Massachusetts Institute of Technology. There, he focused on the role of the RAS oncoproteins in colorectal cancer, using genetically engineered mouse models to elucidate the functional differences between related oncoproteins. He was a Robert Black Fellow of the Damon Runyon Cancer Research Foundation and received the Howard Temin Award K01 from the National Cancer Institute. The Haigis laboratory combines computational and informatic approaches with experimental approaches in genetically engineered mice and human models to study the relationship between Ras signaling, colorectal cancer, and inflammation. This work has provided a mechanistic basis for clinical and epidemiological behaviors of RAS mutant cancers and helped to provide a framework for precision medicine approaches to treating cancers expressing mutant forms of RAS.

Barrett Rollins, MD, PhD

Barrett Rollins, MD, PhD, served from 2004 to 2020 as Dana-Farber’s first Chief Scientific Officer. During his tenure, he helped establish the Lurie Family Imaging Facility in South Boston and the PROFILE project, one of the first efforts that obtained clinically relevant genetic information on every patient seen at a single cancer center. He went on to spearhead a consortium that combines similar data from eighteen centers around the world and makes the information available to all scientists. In his own research, Dr. Rollins's lab elucidated mechanisms that control white blood cell movement throughout the body. He also identified the genetic abnormalities underlying Langerhans Cell Histiocytosis, a rare childhood neoplasm. His observations now form the basis of effective new therapies. Dr. Rollins graduated from Amherst College and received his MD and PhD degrees from Case Western Reserve University. He has been a member of the faculty at Dana-Farber and Harvard Medical School since 1989 where he holds the Linde Family Professorship. He is a member of the American Society for Clinical Investigation, a member of the Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Amherst College awarded him an honorary Doctor of Science.
SPEAKER BIOGRAPHIES

William C. Hahn, MD, PhD

William C. Hahn, MD, PhD, is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School and an Institute Member of the Broad Institute of MIT and Harvard. He serves as an Executive Vice President and the Chief Operating Officer at the Dana-Farber Cancer Institute. His laboratory focuses on using functional genomics to understand how mutations cooperate in cancer to develop rational combination therapies. Bill did both his undergraduate research with Jim Rheinwald, and his graduate work in immunology with Steve Burakoff at DFCI. After completing his medical oncology training at DFCI, he did his postdoctoral work with Bob Weinberg before returning to DFCI in 2001.

Scott A. Armstrong, MD, PhD

Scott A. Armstrong, MD, PhD, is Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School. He is also President of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dr. Armstrong’s research group has made seminal discoveries into leukemia biology and chromatin based epigenetic mechanisms in cancer. This work has spurred the development of several new classes of therapeutic agents that target epigenetic mechanisms and gene activity in cancer with many being tested in clinical trials for both children and adults. Dr. Armstrong has served multiple roles for the American Association for Cancer Research including as a member of the Board of Directors. His work has been recognized with awards such as the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center, the E. Mead Johnson Award from the Society for Pediatric Research and the Dameshek Prize from the American Society of Hematology. He is a member of the National Academy of Medicine.
**Kornelia Polyak, MD, PhD**

**Chloe Hall**, is co-chair of DFCI’s Pediatric Patient and Family Advisory Council (PPFAC) and has been a part of the council since 2017. She was an adolescent patient at the Jimmy Fund Clinic in 2008 and has been receiving follow-up care through the Perini Family Survivors’ Center. Through volunteering, she aspires to help other patients feel hope and support as they face the unique challenges pediatric and young adult cancer diagnoses bring.

**Chloe Hall**, is Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a co-leader of the Dana-Farber Harvard Cancer Center Cancer Cell Biology Program. Dr. Polyak is an internationally recognized leader of breast cancer research. Her laboratory is dedicated to improving the clinical management of breast cancer patients by understanding of breast tumor evolution. Dr. Polyak has devoted much effort to develop new ways to study tumors as a whole and to apply interdisciplinary approaches. Dr. Polyak has received numerous awards including the Paul Marks Prize for Cancer Research, the AACR Outstanding Investigator Award for Breast Cancer Research, and the 14th Rosalind E. Franklin Award for Women in Science. She is a recipient of the NCI Outstanding Investigator award and received a Distinguished Alumna Award from Weil-Cornell. Dr. Polyak was elected as a Fellow of the American Association for the Advancement of Science and the American Association for Cancer Research Academy in 2020, and to the National Academy of Sciences in 2022.
SPEAKER BIOGRAPHIES

Bruce E. Johnson, MD

_Bruce E. Johnson, MD_, is an institute physician at the Dana-Farber Cancer Institute and a co-leader of the Dana-Farber/Harvard Cancer Center Lung Cancer Program in Boston, MA. He is professor of medicine at Harvard Medical School and an ASCO Translational Research Professor. He received his undergraduate degree from Harvard University and his medical degree from the University of Minnesota, and he trained in internal medicine at the University of Chicago. Dr. Johnson completed his medical oncology training at the National Cancer Institute, where he served as a faculty member from 1985 to 1998 and as head of their Lung Cancer Biology section for 6 years. He came to Dana-Farber in 1998 to head the Lowe Center for Thoracic Oncology. Dr. Johnson’s research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies. He has published more than 270 research articles on a variety of topics, including the molecular basis of lung cancers and the development of targeted therapies for patients with specific genomic alterations in lung cancer. He is one of the investigators who discovered epidermal growth factor receptor mutations, which have enhanced the treatment of lung cancer throughout the world. He also led the studies that led to the approval of dabrafenib plus trametinib for BRAF-mutant non–small cell lung cancer. Dr. Johnson served on the American Society for Clinical Oncology (ASCO) Board of Directors from 2008 to 2011, received their Cancer Foundation’s Translational Research Professorship in 2008, and was selected as an ASCO fellow in 2012. He was elected president of ASCO for the 2017-2018 term and served as immediate past president in 2018-2019.

Jenny Dahlstein

_Jenny Dahlstein_, was born in Sweden and grew up in Italy, Russia, Kenya, Ecuador, and Argentina. Treated for triple-negative breast cancer in 2016, Jenny later joined the Adult Patient and Family Advisory Council (PFAC) to contribute to Dana-Farber’s work of centering the voices of patients and family caregivers in all phases of the care continuum. Living with cancer is life-altering and, for some, doesn’t end with treatment. Currently a co-chair of the Adult PFAC, Jenny is interested in the transition into and out of care, and in equitable access to quality care for all.
SPEAKER BIOGRAPHIES

Laurie H. Glimcher, MD

Laurie H. Glimcher, MD is the President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. She is a Member of the National Academy of Sciences, the National Academy of Medicine and Fellow of the American Academy of Arts and Sciences. She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, Repare Therapeutics, Abpro Therapeutics, BioSciences, Inc. Scientific Advisory Boards, the Lasker Award Jury, the American Association for Cancer Research, Association of American Cancer Institutes, and the American Society of Clinical Oncology and served on the Vice President's Blue Ribbon panel. She serves on the Board of Directors of GSK plc and Analog Devices, Inc. Dr. Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science.

James A. DeCaprio, MD

James A. DeCaprio, MD, received his MD degree from the State University of New York at Buffalo, clinical training in Internal Medicine at the University of Chicago, and in Medical Oncology at Dana-Farber Cancer Institute. He performed his postdoctoral studies with David Livingston where they discovered the specific interaction between SV40 Large T antigen and the retinoblastoma tumor suppressor (RB) and the ability of RB to control the cell cycle. He established his own laboratory at DFCI in 1992. His lab has focused on the discovery of fundamental biological processes that when perturbed by DNA tumor viruses or by mutation contribute to cancer. His studies on viral-host cell protein-protein interactions led to the discovery of the cullin-RING-ligase complex containing CUL7, FBXW8, CUL9, and GLMN. More recently, his laboratory studies the contribution of Merkel cell polyomavirus to the highly aggressive skin cancer Merkel cell carcinoma. As part of this effort to discover cellular factors that bind to viral oncogenes, his laboratory discovered the mammalian DREAM (DP, RB-related, E2F, and MuvB) complex and determined that DREAM serves as the master coordinator of cell cycle-dependent gene expression. His laboratory developed an integrated view of the control of cell cycle dependent gene expression linking RB, p53, DREAM, and the MYBL2-MuvB-FOXM1 transcription factors.
SPEAKER BIOGRAPHIES

**Nika Danial, PhD**

*Nika Danial, PhD*, is an Associate Professor of Medicine at Harvard Medical School and the Department of Cancer Biology at the Dana-Farber Cancer Institute. She is Co-Director of the NCI-funded T32 Training Program in Cancer Chemical Biology and Metabolism at Dana-Farber. She received an undergraduate degree in Biological Sciences from Stanford University, and a PhD. in Molecular, Cellular and Biophysical Studies from Columbia University. Her postdoctoral studies in the laboratory of Stanley J. Korsmeyer at the Dana-Farber Cancer Institute focused on the role of BCL-2 family proteins in mitochondrial apoptosis, where she discovered a molecular link between cell survival/death regulatory pathways and metabolism. Dr. Danial's laboratory investigates how cellular fuel usage and fuel flexibility modulate stress responses at the molecular level through alterations in cellular bioenergetics, reductive power and biosynthetic pathways. This research program has led to advances in understanding anabolic and catabolic mechanisms that link altered fuel metabolism and nutrient signaling to diseases such as cancer, diabetes and seizure disorders.

**Edward Chouchani, PhD**

*Edward Chouchani, PhD*, joined the faculty of Harvard Medical School as an Assistant Professor of Cell Biology in 2017. He received his PhD in Biological Sciences at the University of Cambridge and MRC Mitochondrial Biology Unit. He then performed postdoctoral research at the Dana-Farber Cancer Institute and Harvard Medical School. Research in the Chouchani Lab focuses on deciphering molecular mechanisms that drive metabolic disease and using this information to develop targeted therapeutic strategies. Mitochondria are critical hubs for metabolic signaling, and their dysfunction is key in the pathology of metabolic disease. The Chouchani Lab combines mass spectrometry and targeted pharmacological approaches in vivo to understand how mitochondrial redox metabolism controls physiology in clinically informative mouse models of obesity and diabetes.

**Evanna Mills, PhD**

*Evanna Mills, PhD*, received her PhD in immunology at Trinity College Dublin, Ireland under the supervision of Prof. Luke O’Neill where she explored the role of mitochondria in the regulation of inflammatory macrophages. She moved to Boston in 2017 to pursue a post-doc with Ed Chouchani in Dana-Farber Cancer Institute (DFCI) studying adipose tissue physiology and has recently started her independent research group in DFCI/Harvard Medical School. The Mills lab studies the interplay between metabolite signaling and innate immune cell function in models of sterile and classical inflammatory disease.
SPEAKER BIOGRAPHIES

Kimberly Stegmaier, MD

Kimberly Stegmaier, MD, Professor of Pediatrics at Harvard Medical School and the Ted Williams Investigator at Dana-Farber Cancer Institute, has advanced the application of genomics to drug and protein target discovery for pediatric malignancies. She is the Vice Chair for Pediatric Oncology Research and Co-director of the Pediatric Hematologic Malignancy Program at Dana-Farber Cancer Institute and Boston Children's Hospital and an Institute Member of the Broad Institute. She is on the Board of Directors of the American Association for Cancer Research (AACR) and the Chair of the St. Jude Children's Research Hospital Scientific Advisory Board and the former Chair of the AACR Pediatric Cancer Working Group. Dr. Stegmaier is the recipient of numerous awards, such as a Stand Up to Cancer (SU2C) Innovative Research Grant, an A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, the 2016 E. Mead Johnson Award for Research in Pediatrics, and an NCI Outstanding Investigator R35 Award. Dr. Stegmaier received her undergraduate degree from Duke University where she graduated valedictorian, medical degree from Harvard Medical School, and trained in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute.

Julie-Aurore Losman, MD, PhD

Julie-Aurore Losman, MD, PhD, is an Assistant Professor in the Division of Molecular and Cellular Oncology at the Dana-Farber Cancer Institute and an Attending Physician in the Division of Hematology at the Brigham and Women’s Hospital. She completed her MD/PhD training at Columbia University’s College of Physicians and Surgeons and her clinical training in internal medicine at John’s Hopkins Hospital. She then entered the tri-institutional Hematology/Oncology Fellowship Program at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Massachusetts General Hospital. After completing her clinical training, she began her post-doctoral research fellowship in the laboratory of Dr. Gary Gilliland at Brigham and Women’s Hospital. Dr. Gilliland left Harvard to become a Vice President at Merck and Dr. Losman switched her postdoctoral training to Dr. William G. Kaelin, Jr.’s laboratory at Dana-Farber. In 2014, she started her own laboratory at Dana-Farber. Her research focuses on understanding the link between aberrant cellular metabolism and epigenetic dysregulation in leukemia, with the goal of identifying novel therapeutic targets to treat patients with cancer.
SPEAKER BIOGRAPHIES

David Barbie, MD

David Barbie, MD, is a thoracic medical oncologist with the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, an Associate Professor of Medicine at Harvard Medical School, and the Associate Director of the Belfer Center for Applied Cancer Science. Dr. Barbie’s research has had a strong translational focus, studying the role of innate immunity in lung cancer. His early collaborations with Gilead Sciences led to the first TBK1 inhibitor trials using a repurposed multitargeted JAK inhibitor. He was principal investigator of a multi-center lung cancer clinical trial using this first-generation drug and his work also led to similar studies in colorectal and pancreatic cancer. Currently his laboratory is developing ways to co-opt TBK1 signaling to drive an antiviral response that can boost the impact of cancer immunotherapies. As a fellow he was the recipient of an ASCO Young Investigator award and NIH K08 grant. Since starting his laboratory he has also received an ASCI Young Physician Scientist Award and was elected as an ASCI Member in 2019. Currently he is a principal or co-principal investigator on multiple NIH grants including an R01, P01, and 2 U01 grants. He has also received significant funding from the V Foundation, SU2C, the Mark Foundation, the Ludwig Center, and the Parker Institute for Cancer Immunotherapy.

Irene Ghobrial, MD

Irene Ghobrial, MD, completed her MD at Cairo University and a residency in Internal Medicine at Wayne State University in Detroit, Michigan, then trained as a Hematology/Oncology Fellow at the Mayo Clinic in Rochester, Minnesota. She is currently a Professor of Medicine and the Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber Cancer Institute, Harvard Medical School. She is the Director of Translational Research in the Department of Multiple Myeloma, Director of the Center for Prevention of Progression diseases (CPOP), and co-leader of the Lymphoma and Myeloma Program at Dana-Farber. She is the co-leader of the Stand Up to Cancer Myeloma Dream Team—the first Dream Team award for blood cancer, the recipient of the Claire W. and Richard P. Morse Research Award, the Jan Gosta Waldenstrom Award, and the William Dameshek Prize given annually by The American Society of Hematology (ASH) to an individual, younger than 50 who has made outstanding contributions in hematology. Her research focuses on identifying and developing effective therapeutic interventions for precursor conditions of myeloma (Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, MGUS and SMM). The focus of her research is to identify novel biomarkers of disease progression and develop potentially curative therapies in the pre-malignant phase that exploit the immune microenvironment in the bone marrow. She developed a large, patient-empowering observational study for these precursor conditions, the PCROWD study. She is also the PI of the first screening study for multiple myeloma in the US, the PROMISE study, which is currently screening 30,000 high-risk individuals, including those of African descent or with a family history of blood cancer.
K. “Vish” Viswanath, PhD

K. “Vish” Viswanath, PhD, is the Lee Kum Kee Professor of Health Communication in the Department of Social and Behavioral Sciences at the Harvard T. H. Chan School of Public Health (HSPH) and in the McGraw-Patterson Center for Population Sciences at the Dana-Farber Cancer Institute (DFCI). He is also the Faculty Director of the Health Communication Core of the Dana-Farber/Harvard Cancer Center (DF/HCC). Other additional administrative and scientific leadership positions held by Dr. Viswanath include: Director of the Center for Translational Communication Science, DFCI/Harvard Chan; Director, Harvard Chan, India Research Center and Co-Director, Lee Kum Sheung Center for Health and Happiness, Harvard Chan. He is the founding Director of DF/HCC’s Enhancing Communications for Health Outcomes (ECHO) Laboratory.